What this story covers

Viatris Inc.'s 2023 10-K highlights a two-phased strategy: Phase 1 stabilized operations with 15 point 4 billion dollars revenue, 5 point 1 billion dollars adjusted E B I T D A, and 1 point 25 billion dollars debt paydown via divestitures like O T C and women's health businesses. Phase 2 targets growth through acquisitions (Oyster Point) and collaborations (Idorsia) in ophthalmology, cardiology, and immunology. Strong cash flow supported 826 million dollars in shareholder returns. Executive comp is performance-tied with 86 percent approval; board emphasizes oversight and diversity. Risks managed via enterprise framework.

Story snapshot